Aquestive Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Aquestive Therapeutics

01/11/2022 21:02

* Aquestive Therapeutics Inc  AQST.OQ  reported a quarterly
adjusted loss of 23 cents​​ per share for the quarter ended in
September. The mean expectation of seven analysts for the
quarter was for a loss of 31 cents per share.
    * Revenue fell 13.7% to $11.46 million from a year ago;
analysts
expected $11.04 million. 
    * Aquestive Therapeutics Inc's reported EPS for the quarter
was a
loss of 23 cents​.
    * The mean earnings estimate of analysts had risen by
about 13.3%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Aquestive Therapeutics Inc shares had fallen by 25.6% this
quarter and lost 77.6% so far this year.
    * The company reported a quarterly loss of $12.54 million.
    * Wall Street's median 12-month price target for Aquestive
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
1 at 09:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.31          -0.23          Beat
 Jun. 30 2022      -0.36          -0.36          Met
 Mar. 31 2022      -0.41          -0.32          Beat
 Dec. 31 2021      -0.47          -0.38          Beat